All In Biotech

Drug Trial Radar · NCT00960661

A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes

A Randomized Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes Who Were Previously Treated by Basal Insulin Glargine With Either Metformin or Metformin and Sulfonylurea

Last checked: Nov 20, 2026Latest source record: Apr 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,036 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,036

Actual

Start

Sep 2009

Primary completion

Aug 2012

Study completion Aug 2012

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Aug 18, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will compare two combination therapies: 1) Combined Basal Insulin Glargine (once a day), Exenatide (twice a day), and Metformin Therapy; or 2) Combined Basal Insulin Glargine (once a day), Bolus Insulin Lispro (three times a day), and Metformin Therapy, in subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • exenatideDrug

    subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (26 weeks), twice a day

  • insulin lisproDrug

    titrated based on pre-meal glucose level; three times a day

  • MetforminDrug

  • Insulin/ GlargineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30Time frame: Baseline, 30 weeks

Locations

95 sites in 18 countries. Site status is shown where the registry gives one.

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Caba, Argentina

  • Research Site

    Capital Federal, Argentina

  • Research Site

    Ciudad Autonoma de Buenos Aire, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Corrientes, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    San Rafael, Argentina

  • Research Site

    Arlon, Belgium

  • Research Site

    Bonheiden, Belgium

  • Research Site

    Edegem, Belgium

  • Research Site

    Merksem, Belgium

  • Research Site

    Tallinn, Estonia

  • Research Site

    Tartu, Estonia

  • Research Site

    Helsinki, Finland

  • Research Site

    Oulu, Finland

  • Research Site

    Vantaa, Finland

  • Research Site

    Angers, France

  • Research Site

    Auxerre, France

  • Research Site

    Bar-le-Duc, France

  • Research Site

    Douai, France

  • Research Site

    La Roche-sur-Yon, France

  • Research Site

    La Rochelle, France

  • Research Site

    Le Creuzot, France

  • Research Site

    Lille, France

  • Research Site

    Marseille, France

  • Research Site

    Montpellier, France

  • Research Site

    Nanterre, France

  • Research Site

    Pessac, France

  • Research Site

    Rennes, France

  • Research Site

    Strasbourg, France

  • Research Site

    Toulouse, France

  • Research Site

    Vénissieux, France

  • Research Site

    Bad Lauterberg im Harz, Germany

  • Research Site

    Dippoldiswalde, Germany

  • Research Site

    Friedrichsthal, Germany

  • Research Site

    Goch, Germany

  • Research Site

    Grevenbroich, Germany

  • Research Site

    Hamburg, Germany

  • Research Site

    Mainz, Germany

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.